| Name | Title | Contact Details |
|---|
Surgicount Medical is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCA`s vision is to be the partner of choice for physicians, hospitals, and health systems in developing and operating ambulatory surgery centers and surgical hospitals across the country and in enhancing hospital-based surgical departments. SCA owns and/or provides management services to 210 ambulatory surgery centers, surgical hospitals, and hospital surgery departments, in partnership with approximately 7,500 physicians and in affiliation with 110 health systems. SCA`s clinical systems, service line growth strategies, benchmarking processes, and efficiency programs create measurable advantage for surgical facilities – clinically, operationally, and financially.
iSource Solutions, is a Diamond Bar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProStat is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.